DDrare: Database of Drug Development for Rare Diseases

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 100 mg AP1189; ABATACEPT; ACH-0144471; ACTH; ACTHar; ALXN2040 (ACH-0144471); AP1189; APL-2; AVACOPAN; Abatacept; Acetaminophen; Acetate; Acid mycophenolic (Myfortic); Acthar; Acthar Gel; Adalimumab; Adalimumab (Humira); Adrenocorticotrophic hormone ACTH; Advagraf 0,5mg; Advagraf 1mg; Advagraf 5mg; Aldosterone; Aliskiren; Amoxicillin; Angiotensin; Angiotensin II; Apixaban; Apixaban 5 MG; Aprovel (150 mg); Aprovel 150 mg Tablets; Atorvastatin; Atrasentan; Avacopan; BELIMUMAB; BENLYSTA; BENLYSTA®; BENLYSTA® (belimumab); BMS-188667; Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Basiliximab; Belimumab; Belimumab 10 mg; Benlysta; Benlysta (belimumab); Bleselumab; CCX140; CCX140-B; CCX168; CDX; CDX-1135; CXA-10; CYCLOPHOSPHAMIDE; Calcium; Chlorambucil; Ciclofosfamida; Ciclosporin; Clarithromycin; Conventional therapy; Corticosteroid; Corticotropin; CsA; CyA; Cyclophosphamide; Cyclophosphamide and steroids; Cyclosporin; Cyclosporin, low dose steroid; Cyclosporine; Cyclosporins; D-Galactose; Dacortín 2,5mg; Dacortín 30mg; Dacortín 5mg; Dalteparin; Danicopan; Danzhu Fuyuan Granule; Dapagliflozin; Daratumumab; Device: LIPOSORBER® LA-15; Device: LIPOSORBER® LA-15 System; Dexamethasone; Diphenhydramine; ECULIZUMAB; ENDOXAN BAXTER*50CPR RIV 50MG; Eculizumab; Eliquis; Enalapril; Endoxan; Evolocumab; Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab); FCM; FG-3019; FK506; Filgotinib; Fluvastatin; Fragmin; Fresolimumab; GC1008; GFB-887; GSK1550188; GSK1550188 (Belimumab); GZ402669; Galactose; Genoxal; Gold; H.P. Acthar Gel; Hydroxychloroquine; INN not available yet; IRBESARTAN; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous injection; Irbesartan; Irbesartan tablets; Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03; Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC; Jianpixiaozhong particles and Wuse Dietotherapy; LA; LNP023; LT4; Lanraplenib; Lansoprazole; Lansoprazole, amoxicillin, clarithromycin; Lisinopril; Lisinopril, losartan, and atorvastatin; Losartan; Losartan Tablets & QingReMoShen Granule; Losmapimod; MABTHERA; MABTHERA*EV 1FL 50ML 500MG; MEDROL*10CPR DIV 4MG; METHYLPREDNISOLONE; MMF; MMF and Dexamethasone; MOR03087; MOR202; MP and CTX; MabThera; MabThera 100 mg concentrate for solution for infusion; MabThera 500 mg concentrate for solution for infusion; Medrol; Mesenchymal stem cells; Methylprednisolone; Methylprednisone; Mizoribine; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF); Mycophenolate mofetil; Mycophenolate mofetil orally 1000 mg twice a day (BID); Mycophenolate mofetil, low dose steroid; Mycophenolate sodium; Mycophenolic acid; Mycophenolic sodium; Myfortic; Myfortic 180mg Tablets; Myfortic 360mg Tablets; Myfortic plus low-dose steroid; Narsoplimab; Neoral; OMS721 (narsoplimab); Obinutuzumab; Oral Cyclosporine; Orencia; Other: D5W; Other: Normal Saline; Over-encapsulated 75 mg Irbesartan Tablets; Over-encapsulated Irbesartan Tablets; PF-06730512; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; Pegcetacoplan; Pentoxifylline; Perindopril; Pirfenidone; Ponticelli Regimen; Prednisolone; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisona; Prednisone; Prednisone 0,5 mg/kg orally on alternate days; Prednisone, FK506, MMF; Prednisone, ciclosporin and mycophenolate mofetil; Procedure: Plasma exchange; Procedure: Plasmapheresis; Prograf; Propagermanium; RE-021; RE-021 (Sparsentan); RITUXIMAB; RTX; Repository Corticotropin Injection; Rituximab; Rituximab Infusion; Rosiglitazone; Rosiglitazone (Avandia); SPARSENTAN; Sirolimus; Soliris; Solondo; Sparsentan; Sparsentan/Over-encapsulated Sparsentan tablet; Sparsentan/Over-encapsulated Sparsentan tablets; Steroid & Cyclosporin; Sulfate; Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin); Synacthen Depot; Synacthen Depot 1mg; TACROLIMUS; TRU-015; TRUXIMA; TRUXIMAB; TW; Tacrolimus; Tacrolimus Capsules; Tacrolimus combined with prednisone; Tetracosactide; Tetracosactide hexacetaat; The Comprehensive Treatment Regimen of Traditional Chinese Medicine; The immunosuppressive agents; Tripterygium; Tripterygium Wilfordii; Tripterygium wilfordii; Tripterygium wilfordii (TW); Truxima; URBASON*IM EV 1F 250MG+1F 5ML; Urbason; VB119; VX-147; VX147; Valproic Acid; Valproic acid; Valsartan; Vitamin D; Voclosporin; Zestril; [CCX140-B];  LNP023 HYDROCHLORIDE SALT

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04424862 (ClinicalTrials.gov)	June 2020	7/6/2020	Multitarget Therapy for Idiopathic Membranous Nephropathy	Multitarget Therapy for Idiopathic Membranous Nephropathy	Efficacy	Drug: Prednisone , ciclosporin and mycophenolate mofetil;Drug: Ponticelli Regimen	Beijing Friendship Hospital	NULL	Not yet recruiting	18 Years	70 Years	All	78	Phase 4	China
2	NCT03170323 (ClinicalTrials.gov)	July 1, 2018	26/5/2017	Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy	A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy	Idiopathic Membranous Nephropathy	Drug: Mycophenolate Mofetil;Drug: Cyclosporins	Guangdong Provincial People's Hospital	NULL	Recruiting	18 Years	N/A	All	128	Phase 4	China
3	NCT02921789 (ClinicalTrials.gov)	May 22, 2017	30/9/2016	Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients	A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients	Kidney Transplantation;Focal Segmental Glomerulosclerosis (FSGS)	Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: Prednisone	Astellas Pharma Global Development, Inc.	Kyowa Kirin Co., Ltd.	Recruiting	18 Years	N/A	All	60	Phase 2	United States;Canada
4	NCT01282073 (ClinicalTrials.gov)	March 2011	19/1/2011	Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy	A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy	Glomerulonephritis, Membranous	Drug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin , low dose steroid	Kyungpook National University	Hanmi Pharmaceutical Company Limited	Recruiting	18 Years	N/A	Both	62	Phase 3	Korea, Republic of
5	NCT00404833 (ClinicalTrials.gov)	January 2003	27/11/2006	Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental	A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)	Glomerulonephritis, Membranous;Glomerulosclerosis, Focal	Drug: prednisolone and mycophenolate mofetil;Drug: prednisolone and chlorambucil	Hospital Authority, Hong Kong	The University of Hong Kong	Completed	18 Years	65 Years	Both	16	Phase 3	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00135967 (ClinicalTrials.gov)	May 2002	25/8/2005	Mycophenolate Mofetil in Membranous Nephropathy	Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study	Glomerulonephritis, Membranous	Drug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9	Radboud University	Hoffmann-La Roche	Completed	18 Years	75 Years	Both	30	Phase 2;Phase 3	Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04424862
(ClinicalTrials.gov)

June 2020

7/6/2020

Multitarget Therapy for Idiopathic Membranous Nephropathy

Efficacy

Drug: Prednisone , ciclosporin and mycophenolate mofetil;Drug: Ponticelli Regimen

Beijing Friendship Hospital

NULL

Not yet recruiting

18 Years

70 Years

All

Phase 4

China

NCT03170323
(ClinicalTrials.gov)

July 1, 2018

26/5/2017

Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy

A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy

Drug: Mycophenolate Mofetil;Drug: Cyclosporins

Guangdong Provincial People's Hospital

NULL

Recruiting

18 Years

N/A

All

128

Phase 4

China

NCT02921789
(ClinicalTrials.gov)

May 22, 2017

30/9/2016

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Kidney Transplantation;Focal Segmental Glomerulosclerosis (FSGS)

Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: Prednisone

Astellas Pharma Global Development, Inc.

Kyowa Kirin Co., Ltd.

Recruiting

18 Years

N/A

All

Phase 2

United States;Canada

NCT01282073
(ClinicalTrials.gov)

March 2011

19/1/2011

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy

A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy

Glomerulonephritis, Membranous

Drug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin , low dose steroid

Kyungpook National University

Hanmi Pharmaceutical Company Limited

Recruiting

18 Years

N/A

Both

Phase 3

Korea, Republic of

NCT00404833
(ClinicalTrials.gov)

January 2003

27/11/2006

Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental

A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)

Glomerulonephritis, Membranous;Glomerulosclerosis, Focal

Drug: prednisolone and mycophenolate mofetil;Drug: prednisolone and chlorambucil

Hospital Authority, Hong Kong

The University of Hong Kong

Completed

18 Years

65 Years

Both

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00135967
(ClinicalTrials.gov)

May 2002

25/8/2005

Mycophenolate Mofetil in Membranous Nephropathy

Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study

Glomerulonephritis, Membranous

Drug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9

Radboud University

Hoffmann-La Roche

Completed

18 Years

75 Years

Both

Phase 2;Phase 3

Netherlands